CRPOF News and Press, Ceapro Inc From 11/15/23

The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

PGX processing unit with a 10X (100 L) vessel capacity to be installed and tested at NATEX pilot testing facility in Austria Yeast beta glucan (YBG) to be the first bio active to be processed at this location EDMONTON, Alberta, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. ...

- $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace reorganization - Ended the quarter with $11.3 million in cash allowing funding fo...

– Exclusive agreement extended from 3 to 5 years until December 31, 2026 – Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market – Offering of new preservative free dry prod...

– New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products – EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the ...

EDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic ind...

EDMONTON, Alberta, June 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic...

2023-05-25 10:10:39 ET Ceapro press release ( OTCQX:CRPOF ): Q1 GAAP EPS of C$0.00. Revenue of C$3.49M (-43.4% Y/Y). For further details see: Ceapro GAAP EPS of C$0.00, revenue of C$3.49M

– Q1 2023 sales of $3,500,000 vs $6,172,000 in Q1 2022 – Ended the quarter with $12.6 million in cash allowing funding for planned pipeline development EDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: ...